Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results
- PMID: 11251004
- DOI: 10.1200/JCO.2001.19.6.1734
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results
Abstract
Purpose: To determine the changes in clinical trials and outcomes of patients with advanced-stage non-small-cell lung cancer (NSCLC) treated on phase III randomized trials initiated in North America from 1973 to 1994.
Patients and methods: Phase III trials for patients with advanced-stage NSCLC were identified through a search of the National Cancer Institute's Cancer Therapy Evaluation Program database from 1973 to 1994, contact with Cooperative Groups, and by literature search of MEDLINE. Patients with advanced NSCLC treated during a similar time interval were also examined in the SEER database. Trends were tested in the number of trials, in the number and sex of patients entered on the trials, and in survival over time.
Results: Thirty-three phase III trials were initiated between 1973 and 1994. Twenty-four trials (73%) were initiated within the first half of this period (1973 to 1983) and accounted for 5,359 (64%) of the 8,434 eligible patients. The median number of patients treated per arm of the trials rose from 77 (1973 to 1983) to 121 (1984 to 1994) (P <.001). Five trials (15%) showed a statistically significant difference in survival between treatment arms, with a median prolongation of the median survival of 2 months (range, 0.7 to 2.7 months).
Conclusion: Analysis of past trials in North America shows that the prolongation in median survival between two arms of a randomized study was rarely in excess of 2 months. Techniques for improved use of patient resources and appropriate trial design for phase III randomized therapeutic trials with patients with advanced NSCLC need to be developed.
Comment in
-
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results.J Clin Oncol. 2001 Oct 15;19(20):4089. J Clin Oncol. 2001. PMID: 11600614 Clinical Trial. No abstract available.
Similar articles
-
Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.Cancer. 2006 May 15;106(10):2208-17. doi: 10.1002/cncr.21869. Cancer. 2006. PMID: 16604529
-
[Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].Onkologie. 2005 Mar;28 Suppl 1:1-28. doi: 10.1159/000084364. Epub 2005 Mar 30. Onkologie. 2005. PMID: 15802886 Review. German.
-
Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America.Cancer. 2002 Oct 1;95(7):1528-38. doi: 10.1002/cncr.10841. Cancer. 2002. PMID: 12237922
-
Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress.J Clin Oncol. 1999 Jun;17(6):1794-801. doi: 10.1200/JCO.1999.17.6.1794. J Clin Oncol. 1999. PMID: 10561217
-
Locally advanced non-small cell lung cancer: do we know the questions? A survey of randomized trials from 1966-1993.J Clin Epidemiol. 1996 Feb;49(2):183-92. doi: 10.1016/0895-4356(95)00518-8. J Clin Epidemiol. 1996. PMID: 8606319 Review.
Cited by
-
Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC Paralogs.Cancer Discov. 2024 May 1;14(5):804-827. doi: 10.1158/2159-8290.CD-23-0656. Cancer Discov. 2024. PMID: 38386926 Free PMC article.
-
Healthcare Costs and Resource Utilisation of Italian Metastatic Non-Small Cell Lung Cancer Patients.Cancers (Basel). 2024 Jan 30;16(3):592. doi: 10.3390/cancers16030592. Cancers (Basel). 2024. PMID: 38339345 Free PMC article.
-
Mutations in KMT2C, BCOR and KDM5C Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer.Cancers (Basel). 2022 Jun 6;14(11):2816. doi: 10.3390/cancers14112816. Cancers (Basel). 2022. PMID: 35681795 Free PMC article.
-
Cholesterol-Lowering Drugs on Akt Signaling for Prevention of Tumorigenesis.Front Genet. 2021 Sep 16;12:724149. doi: 10.3389/fgene.2021.724149. eCollection 2021. Front Genet. 2021. PMID: 34603386 Free PMC article. Review.
-
Preliminary Report on Computed Tomography Radiomics Features as Biomarkers to Immunotherapy Selection in Lung Adenocarcinoma Patients.Cancers (Basel). 2021 Aug 7;13(16):3992. doi: 10.3390/cancers13163992. Cancers (Basel). 2021. PMID: 34439148 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous